iThriveMD Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A clinic can document a treatment offering without demonstrating how well that particular service works. That distinction is central to evaluating iThriveMD, a longevity and weight-management clinic advertising compounded injectable semaglutide and tirzepatide. Its public pages describe consultations, laboratory testing, home treatment, clinic visits and recurring packages. They provide meaningful operational detail, but they do not establish measured outcomes for the clinic’s preparations or validate its microdosing claims through provider-specific clinical research.

This review separates three questions: what iThriveMD says it supplies, what independent clinical evidence can establish, and what a prospective patient still needs in writing. The documentation was consulted October 19, 2026; some pages could not be reloaded during the final refresh, so current terms need confirmation. The most consequential gaps concern the dispensing pharmacy, differences between general and microdosing screening, and prices that mix monthly labels with 28-day billing and prepaid weeks.

At a glance

Documented medications: iThriveMD advertises compounded semaglutide and tirzepatide administered through subcutaneous injections; microdosing is offered only with tirzepatide.
Sources: [13]
Geographic access: The clinic advertises telehealth across California and Arizona, with the same member pricing for telehealth and in-person care.
Sources: [10]
Introductory prices: Monthly-plan advertisements show semaglutide at $199 initially, then $299, and tirzepatide at $299 initially, then $399. Billing is every 28 days; the $100 promotion applies only to the first month and not to packages.
Sources: [7] [8] [10]
Screening discrepancy: The homepage says baseline labs precede any plan, while the microdosing page says neither a particular BMI nor lab work is required to enroll.
Sources: [10] [6]
Evidence boundary: The provider acknowledges that compounded drugs are not FDA approved and its results have not been independently verified. FDA approval of a specific product does not extend to a clinic’s compounded preparation.
Sources: [5] [1]

The business behind the treatment claims

iThriveMD describes itself as a medical clinic focused on longevity and the underlying causes of fatigue, weight gain, hormonal changes and age-related decline. Weight management sits within that broader business, alongside advertised B12 injections, IV therapy, hormone replacement therapy and diagnostic testing. Those offerings establish the clinic’s scope, not evidence that combining these services improves GLP-1 outcomes. The weight-loss page says no insurance or referral is required.

Its published team identifies Samir Damani, MD, as founder and cardiovascular specialist, Aubrey Anderson as a naturopathic doctor, and Thomas Macsay as a naturopathic doctor and vice president of clinical operations. These are provider-published credentials, not independently verified licenses. They also do not establish which professional would evaluate a particular patient, prescribe medication or handle a complication. A prospective patient should ask who carries each responsibility.

A referral disclosure names Vishal Verma, MD, Samir Damani, MD, Empower Aesthetics Medical Group, Inc., and iThriveMD PC, describing financial interests or service relationships among listed parties. That disclosure is relevant organizational information, not evidence of improper care. The practical issue is identifying the entity taking payment and the clinician responsible for treatment. Our guide to what public provider documents can prove explains why published descriptions and independently established performance are different categories.

Sources: [11] [10] [12]

What is offered, and which evidence belongs to it

The clinic describes two main medication options: compounded semaglutide and compounded tirzepatide, customized to dosing needs and selected by its medical team. Its general GLP page describes subcutaneous injections. This is not documentation that a patient receives an FDA-approved branded product. The semaglutide page says dispensing occurs through a LegitScript-certified facility, but the consulted material does not identify that facility by name, address or license. That claim also does not identify who compounds the preparation.

FDA states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence, nor does it validate a provider. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. These are product and prescribing questions, not a categorical judgment about iThriveMD.

The clinic’s own disclaimer acknowledges both nonapproval and the absence of independently verified results. Readers should therefore avoid treating research on a studied drug product as a performance report for this service. Our explanation of approved medicines and compounded preparations develops that distinction. Before purchasing, request the pharmacy identity, exact formulation and presentation, and an explanation of why that preparation is being proposed rather than an approved product.

Sources: [13] [7] [5] [1]

Microdosing needs its own evidence conversation

iThriveMD offers microdosing only with tirzepatide. Its general page separately advertises semaglutide maintenance plans for people who have completed a full GLP weight-loss program. These are distinct offerings, not interchangeable names for the same treatment. The microdosing page calls the approach off-label and says FDA has not specifically studied or approved those lower doses. That acknowledgment is important, but it does not supply clinical validation of the program’s claimed benefits.

The documented marketing contains tensions. One description promotes microdosing without nausea or stomach problems, while its own FAQ acknowledges possible digestive or appetite-related effects. Broader material suggests results comparable to regular programs, whereas the dedicated page distinguishes microdosing’s goals from substantial weight loss. Neither promotional statement establishes comparative effectiveness. Ask what outcome is actually being targeted, how it will be measured, and what evidence supports that specific formulation and protocol.

STEP 1 and SURMOUNT-1 are research on defined study populations and treatments, not evaluations of iThriveMD’s compounded preparations or microdosing service. Their findings cannot predict an individual result or validate a different protocol. The distinction is explained in why a clinical trial is not a company performance report. Here, the useful finding is the boundary of the evidence, not a borrowed weight-loss percentage that could imply an unsupported clinic outcome.

Sources: [13] [6] [3] [4]

Screening and follow-up: documented steps, unresolved differences

The published intake sequence begins with an online questionnaire about health and goals, followed by a clinical consultation reviewing diagnostic labs and a personalized plan. Treatment can begin in a clinic or at home if eligible, with subsequent tracking and adjustments. The general GLP page offers free eligibility assessments and says diabetes is not required. It describes possible eligibility for adults with BMI over 27 and weight-related conditions, or BMI over 30; that wording is not a guarantee of prescribing.

Laboratory requirements are less coherent across programs. The homepage promises diagnostic testing and baseline labs before any plan begins. The microdosing page, however, says no particular BMI or lab work is required to enroll. Enrollment and treatment initiation might be different stages, but the public documentation does not reconcile them. Ask which tests, if any, must be completed before prescribing, who reviews them and whether their costs are included in the specific package.

The general weight-loss page says every plan includes monthly consultations, metabolic lab testing and real-time progress tracking. Microdosing specifies an initial 30-minute consultation and monthly 15-minute follow-ups. The tirzepatide page promises first-visit injection training, video tutorials and ongoing support. These are useful service commitments, but response times and between-visit clinical messaging are not documented. As our guide to clinical follow-up beyond renewal notices explains, appointment frequency alone does not establish how problems are handled.

Sources: [7] [13] [10] [6] [12] [8] [2]

The standard prices are visible, but the billing units need clarification

The medication pages publish introductory and longer-package prices rather than requiring a consultation to reveal every amount. However, monthly labels sit beside 28-day billing and packages lasting 12, 24 or 48 weeks. Those periods are not equivalent to three, six or twelve calendar months. The table preserves the advertised figures without calculating an unconfirmed package total. All entries concern the clinic’s compounded injectable programs, not prices for an FDA-approved branded presentation.

The $100 promotion applies only to the first month and cannot be applied to packages; regular pricing follows. Longer packages advertise prepaid weeks and payment-plan availability. Semaglutide’s displayed package discounts are 10%, 15% and 20%, with claimed monthly savings of $29.90, $44.85 and $59.80. Tirzepatide’s are 25%, 35% and 50%, with claimed savings of $99.75, $139.65 and $199.50. These are provider-advertised comparisons, not independently calculated savings.

The tirzepatide page says its price stays the same regardless of dose, while general weight-loss material says cost depends on dose. Obtain a program-specific quote resolving that difference. The documentation also does not unequivocally establish the full standard-package charge from the displayed monthly-style figures. A useful written quote should show the amount collected today, subsequent charge, billing dates, medication presentation and quantity, included services, and any separate laboratory or delivery fees.

Advertised standard compounded injectable program prices
Plan label	Semaglutide display	Tirzepatide display
Monthly; billed every 28 days; no long-term commitment advertised	$199 introductory; $299 per month afterward	$299 introductory; $399 per month afterward
3-month; 12 weeks prepaid; shipped every 28 days; payment plan available	$269.10; advertised 10% off	$299.25; advertised 25% off
6-month; 24 weeks prepaid; shipped every 28 days; payment plan available	$254.15; advertised 15% off	$259.35; advertised 35% off
12-month; 48 weeks prepaid; shipped every 28 days; payment plan available	$239.20; advertised 20% off	$199.50; advertised 50% off

Sources: [7] [8] [10] [12]

Microdosing packages, payment options and renewal exposure

Tirzepatide microdosing has more explicit package totals: $585 for 12 prepaid weeks, advertised as $195 per month; $1,053 for 24 prepaid weeks, advertised as $175.50 per month with 10% off; and $1,755 for 48 prepaid weeks, advertised as $146.25 per month with 25% off. Each lists shipping every 28 days and a payment-plan option. The six-month offer claims $20 monthly savings, which does not exactly match its displayed monthly-price comparison; the twelve-month claim is $48.75.

The homepage states that packages are paid in full at purchase and automatically renew at the selected package interval. That does not clearly reconcile with the medication pages’ payment-plan options. A separate notice says all memberships are charged every 28 days. These statements leave uncertainty about financing, package renewal and recurring collection. Payment alternatives should not be mistaken for mandatory prepayment, but neither should the advertised option be assumed available without approval or additional terms.

No financing provider, interest terms or approval requirements are documented. Nor do the consulted materials establish cancellation deadlines, cancellation charges, renewal-stop procedures or refund boundaries. The monthly plans’ no-long-term-commitment language does not answer those questions for prepaid packages. Before authorizing payment, request the applicable agreement and confirmation of whether ending care stops future charges, whether unused portions can be refunded, and how any financing obligation is handled separately.

Sources: [6] [10] [5] [7] [8]

Where treatment happens and who handles the shipment

The homepage limits advertised telehealth availability to California and Arizona and promises the same member pricing across settings. The directory lists California addresses in Roseville, Walnut Creek, Sunnyvale and Laguna Niguel, while Scottsdale is labeled a telehealth appointment. That supports a regional service description, not nationwide access or a verified uniform count of physical clinics. Confirm that the desired location provides the specific service and that a clinician can treat you where you will be located.

For tirzepatide, iThriveMD offers shipment to the home or clinic visits for support and injections. Semaglutide advertising includes clinical oversight and coaching. The documentation does not specify a carrier, delivery fees, arrival window, refrigeration arrangements or replacement policy for damaged or delayed medication. Shipping every 28 days describes a dispatch cadence, not arrival timing, and a package’s duration does not independently establish the quantity of medication supplied.

These missing logistics matter because the dispensing pharmacy is also unnamed in the consulted material. Ask who ships the medication and who resolves temperature, labeling or supply concerns. FDA explicitly recommends not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. FDA also reports measurement and administration errors with compounded products; patients should clarify instructions with their prescriber or pharmacist rather than derive doses from a review.

Sources: [10] [9] [8] [7] [1]

What to establish before the free assessment becomes a purchase

The tirzepatide page says iThriveMD does not accept insurance for that treatment and permits HSA or FSA payment. For semaglutide, it says those funds may be usable and documentation may support reimbursement when a plan includes out-of-network benefits. Neither statement guarantees reimbursement or establishes an individual account’s rules. The clinic’s suggestion that cash pricing can be cheaper than insurance copays is a commercial claim, not a comparison established for every patient.

The public intake questionnaire, free eligibility assessment and listed clinic locations are documented entry points. The consulted material does not establish a patient portal, Spanish-language care, clinical messaging channel, appointment turnaround or support response standard. Ask for both routine and urgent contact instructions, not simply a purchasing contact. Also request confirmation of the minimum age, complete eligibility exclusions and any residency requirements; those details are not fully specified in the documentation.

A productive consultation should connect the proposed product to a clinical rationale, identify the prescriber and pharmacy, and establish measurable follow-up goals. NIDDK advises discussing health conditions, other medicines, supplements, allergies, pregnancy plans, costs and side effects with a clinician. That conversation should precede choosing a long package for its discount. The missing public information does not prove deficient care, but it does mean a prospective patient cannot settle these questions from the advertising alone.

Sources: [8] [7] [13] [9] [2]

Questions & answers

Does iThriveMD supply branded Wegovy or Zepbound?

The consulted documentation establishes compounded semaglutide and tirzepatide offerings, not that either branded product is supplied. Ask for the exact prescribed product, formulation, presentation and dispensing pharmacy. An ingredient name alone does not establish that a preparation is the FDA-approved product used in a particular trial.

Sources: [13] [1]

Can I use iThriveMD outside California or Arizona?

The homepage advertises telehealth across California and Arizona. The consulted documentation does not confirm availability elsewhere. Its directory lists several California clinic addresses and describes Scottsdale as a telehealth appointment, so do not assume every listed market has an in-person clinic. Confirm availability for your location before paying.

Sources: [10] [9]

Are laboratory tests required for microdosing?

The microdosing page says lab work is not required to enroll, while the homepage says baseline labs precede any plan. Those statements are not reconciled publicly. Ask whether enrollment differs from prescribing, which tests your program requires, and whether initial and subsequent testing are included or separately billed.

Sources: [6] [10] [12]

Is the $199 semaglutide price ongoing?

No. The monthly advertisement shows $199 initially and $299 per month afterward, with billing every 28 days. The homepage restricts the $100 discount to the first month and excludes packages. A 28-day billing interval is not a calendar month; request the actual next charge date and amount.

Sources: [7] [10]

Can I cancel a prepaid package and receive unused money back?

The consulted materials do not establish that right. They describe automatic package renewal but do not provide clear cancellation deadlines, procedures or refund terms. Cancellation and refund eligibility are separate questions. Obtain the package-specific agreement before purchase, including what happens to unused treatment and any payment-plan balance.

Sources: [10] [5]

What injection support does iThriveMD document?

The tirzepatide page promises first-visit injection training, video tutorials and ongoing support, plus a choice of home shipment or clinic visits for support and injections. It does not specify support response times. Confirm whom to contact about instructions, symptoms or delivery concerns and what assistance is available between scheduled visits.

Sources: [8]

Our assessment

iThriveMD documents a substantive regional service: compounded injectable options, consultation schedules, injection instruction, clinic access and published prices. Those details are useful, but they do not establish provider-specific effectiveness or validate microdosing comparisons. The strongest next step is documentary clarification, not reliance on promotional outcomes: obtain the pharmacy identity, exact product, screening requirements, all-in charge, renewal schedule and cancellation agreement. Its public materials provide a starting point for evaluating care, while leaving enough product, billing and service responsibilities unresolved that a long prepaid package warrants particular scrutiny.

Visit iThriveMD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

iThriveMD Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01The business behind the treatment claims

02What is offered, and which evidence belongs to it

03Microdosing needs its own evidence conversation

04Screening and follow-up: documented steps, unresolved differences

05The standard prices are visible, but the billing units need clarification

06Microdosing packages, payment options and renewal exposure

07Where treatment happens and who handles the shipment

08What to establish before the free assessment becomes a purchase